Nifedipine and Enalapril
PreclinicalSmall molecule
Nifedipine and Enalapril is one of 26 small molecule programs targeting Hypertension. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Benicar
NovartisPreclinical
Zebeta
TevaPreclinical
Edarbi
TakedaPreclinical
Aceon
Institut de Recherches Internationales ServierPreclinical
Winrevair
Merck & Co.Preclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nifedipine and Enalapril. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TThe Cleveland Clinic